insulin drugs glp 1 receptor agonist market GLP-1 Size & Trends 2035 GLP-1 Receptor Agonist Market Size,

Rationale Obesity remains a major global health challenge, severely affecting metabolic and cardiovascular health

Preclinical studies have confirmed that GIPRGLP1R coagonists improve several hallmarks of metabolic syndrome, such as obesity, hyperglycemia, and dyslipidemia

Adolescents with obesity prescribed a GLP-1 receptor agonist are less likely to have suicidal ideation or a suicide attempt than those with obesity treated with lifestyle intervention, according to new data

For professionals in pharma, clinical research, and regulatory affairs, this space is evolving fastand full of opportunity

Tirzepatide is a new drug targeting glucagon-like peptide 1(GLP1) and gastric inhibitory polypeptide (GIP) receptors

Drugmaker Eli Lilly announced the FDA approved its oral GLP-1 pill, called Foundayo.